PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
July 20, 2023 09:07 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
October 07, 2022 09:20 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid...
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
May 27, 2020 06:45 ET
|
Zynerba Pharmaceuticals, Inc.
- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist - - Safety Data Reinforce...
Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population
March 03, 2020 12:07 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Q BioMed Files for Orphan Drug Designation with U.S. FDA for Autism Spectrum Disorder Subtype
June 28, 2019 08:32 ET
|
Q BioMed Inc.
Currently no effective treatment exists for the 20,000 children in the U.S. and 250,000 born worldwide each year with pediatric minimally verbal autism (PMVA) NEW YORK, June 28, 2019 (GLOBE...
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
June 11, 2019 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
March 07, 2019 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
- Topline Data from BRIGHT Study Expected in the First Half 2020 - - Company Selects Zygel™ as Brand Name for ZYN002 CBD Transdermal Gel - DEVON, Pa., March 07, 2019 (GLOBE NEWSWIRE) -- Zynerba...
Elsevier Shines Light on Autism Treatments with New Book Series
July 11, 2017 04:00 ET
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - July 11, 2017) - Elsevier, the information analytics company specializing in science and health, today announced the publication of a new book series, Critical...
Autism Speaks Canada Walk Will Raise Funds and Spread Awareness about Autism - Support this important FUNdraiser
May 25, 2016 09:25 ET
|
Autism Speaks Canada
OTTAWA, May 25, 2016 (GLOBE NEWSWIRE) -- Autism Speaks Canada, part of North America's largest autism science and advocacy organization, announced that the Autism Speaks Canada Walk, Ottawa 2016...
Charitable "Believe in Yourself" Clothing Line Launched in Support of Fullerton Cares Autism Foundation
March 09, 2015 07:00 ET
|
Fullerton Cares
FULLERTON, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- With autism affecting 1:68 children, the child of Fullerton Cares founder Larry Houser is far from being just a number. After inspiring the...